Therapeutic Area | MeSH |
---|---|
neoplasms | D009369 |
hemic and lymphatic diseases | D006425 |
immune system diseases | D007154 |
Tradename | Company | Number | Date | Products |
---|---|---|---|---|
DAUNOXOME | Galen Pharma | N-050704 DISCN | 1996-04-08 | 1 products |
Tradename | Company | Number | Date | Products |
---|---|---|---|---|
DAUNORUBICIN HYDROCHLORIDE | Hikma Pharmaceuticals | N-050731 RX | 1998-01-30 | 1 products, RLD, RS |
Tradename | Company | Number | Date | Products |
---|---|---|---|---|
VYXEOS | Celator Pharmaceuticals | N-209401 RX | 2017-08-03 | 1 products, RLD, RS |
Brand Name | Status | Last Update |
---|---|---|
daunorubicin hydrochloride | ANDA | 2024-12-25 |
vyxeos | New Drug Application | 2022-09-27 |
Expiration | Code | ||
---|---|---|---|
CYTARABINE / DAUNORUBICIN, VYXEOS, CELATOR PHARMS | |||
2028-03-30 | ODE-350 | ||
2024-08-03 | ODE-287 | ||
2024-03-30 | NPP |
Patent | Expires | Flag | FDA Information |
---|---|---|---|
Cytarabine / Daunorubicin, Vyxeos, Celator Pharms | |||
10028912 | 2032-10-15 | DP | U-3149, U-3150 |
10166184 | 2032-10-15 | DP | U-3149 |
10835492 | 2032-10-15 | U-3150 | |
8092828 | 2029-04-01 | U-3147 | |
8022279 | 2027-09-14 | DP | U-3147 |
7850990 | 2027-01-23 | DP | U-3147 |
9271931 | 2027-01-23 | DP | |
8518437 | 2026-06-07 | DP | |
8431806 | 2025-04-22 | DP | U-3147 |
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
---|---|---|---|---|---|---|---|---|---|
Leukemia | D007938 | — | C95 | 2 | 2 | 1 | — | — | 5 |
Myeloid leukemia acute | D015470 | — | C92.0 | 2 | 2 | 1 | — | — | 5 |
Myeloid leukemia | D007951 | — | C92 | 2 | 2 | 1 | — | — | 5 |
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
---|---|---|---|---|---|---|---|---|---|
Precursor cell lymphoblastic leukemia-lymphoma | D054198 | — | C91.0 | — | 1 | — | — | — | 1 |
Lymphoid leukemia | D007945 | — | C91 | — | 1 | — | — | — | 1 |
Drug common name | Daunorubicin |
INN | daunorubicin |
Description | Daunorubicin is a natural product found in Actinomadura roseola. It has a role as an antineoplastic agent and a bacterial metabolite. It is an anthracycline, a member of tetracenequinones, a member of p-quinones and an aminoglycoside antibiotic. It is a conjugate base of a daunorubicin(1+). It derives from a hydride of a tetracene. |
Classification | Small molecule |
Drug class | antineoplastic antibiotics (daunorubicin type) |
Image (chem structure or protein) | ![]() |
Structure (InChI/SMILES or Protein Sequence) | COc1cccc2c1C(=O)c1c(O)c3c(c(O)c1C2=O)C[C@@](O)(C(C)=O)C[C@@H]3O[C@H]1C[C@H](N)[C@H](O)[C@H](C)O1 |
PDB | — |
CAS-ID | 20830-81-3 |
RxCUI | — |
ChEMBL ID | CHEMBL178 |
ChEBI ID | 41977 |
PubChem CID | 30323 |
DrugBank | DB00694 |
UNII ID | ZS7284E0ZP (ChemIDplus, GSRS) |